Bank Julius Baer & Co. Ltd Zurich Has $27.56 Million Stock Position in Boston Scientific Co. (NYSE:BSX)

Bank Julius Baer & Co. Ltd Zurich grew its stake in Boston Scientific Co. (NYSE:BSX) by 0.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 291,426 shares of the medical equipment provider’s stock after buying an additional 1,316 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Boston Scientific were worth $27,557,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Adero Partners LLC increased its position in shares of Boston Scientific by 3.3% in the 4th quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider’s stock valued at $334,000 after buying an additional 120 shares in the last quarter. Grove Bank & Trust increased its position in shares of Boston Scientific by 4.4% in the 4th quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider’s stock valued at $261,000 after buying an additional 122 shares in the last quarter. PFG Investments LLC increased its position in shares of Boston Scientific by 1.6% in the 4th quarter. PFG Investments LLC now owns 8,113 shares of the medical equipment provider’s stock valued at $725,000 after buying an additional 125 shares in the last quarter. Stonegate Investment Group LLC increased its position in shares of Boston Scientific by 1.6% in the 4th quarter. Stonegate Investment Group LLC now owns 7,827 shares of the medical equipment provider’s stock valued at $699,000 after buying an additional 126 shares in the last quarter. Finally, Ashton Thomas Securities LLC increased its position in shares of Boston Scientific by 1.3% in the 3rd quarter. Ashton Thomas Securities LLC now owns 9,968 shares of the medical equipment provider’s stock valued at $835,000 after buying an additional 129 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Activity

In related news, CFO Daniel J. Brennan sold 67,333 shares of the company’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the completion of the sale, the chief financial officer now directly owns 225,808 shares in the company, valued at $23,764,033.92. This represents a 22.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $104.25, for a total value of $487,368.75. Following the sale, the executive vice president now owns 28,454 shares of the company’s stock, valued at approximately $2,966,329.50. This represents a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 137,322 shares of company stock worth $14,321,068. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Performance

NYSE:BSX opened at $99.15 on Friday. The stock has a fifty day moving average price of $100.45 and a 200-day moving average price of $91.19. The company has a market cap of $146.33 billion, a price-to-earnings ratio of 79.32, a PEG ratio of 2.79 and a beta of 0.77. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. Boston Scientific Co. has a fifty-two week low of $65.52 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, equities analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on BSX. Citigroup increased their target price on Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Morgan Stanley increased their target price on Boston Scientific from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Royal Bank of Canada increased their target price on Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. UBS Group increased their target price on Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Finally, Wells Fargo & Company increased their target price on Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $108.91.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.